C4 Therapeutics, Inc. (CCCC) Misses Q4 EPS by 188c

C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q4 EPS of ($2.62), $1.88 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $31.1 million versus the consensus estimate of $9.87 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance
• Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance